United Therapeutics Corp. (NASDAQ:UTHR) CFO John Maxim Ferrari sold 4,500 shares of United Therapeutics Corp. stock in a transaction that occured on Thursday, August 15th. The shares were sold at an average price of $71.14, for a total transaction of $320,130.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
A number of analysts have recently weighed in on UTHR shares. Analysts at Argus raised their price target on shares of United Therapeutics Corp. from $75.00 to $85.00 in a research note to investors on Monday, August 5th. They now have a “buy” rating on the stock. Separately, analysts at Guggenheim raised their price target on shares of United Therapeutics Corp. from $61.00 to $69.00 in a research note to investors on Tuesday, July 30th. They now have a “neutral” rating on the stock. Finally, analysts at Standpoint Research downgraded shares of United Therapeutics Corp. from a “buy” rating to a “hold” rating in a research note to investors on Tuesday, July 30th.
Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have given a buy rating to the stock. United Therapeutics Corp. has an average rating of “Hold” and an average price target of $63.10.
United Therapeutics Corp. (NASDAQ:UTHR) traded up 0.04% during mid-day trading on Monday, hitting $71.235. The stock had a trading volume of 173,167 shares. United Therapeutics Corp. has a 1-year low of $44.51 and a 1-year high of $76.95. The stock’s 50-day moving average is $70.93 and its 200-day moving average is $64.20. The company has a market cap of $3.556 billion and a price-to-earnings ratio of 12.28.
United Therapeutics Corp. (NASDAQ:UTHR) last posted its quarterly earnings results on Thursday, July 25th. The company reported $1.52 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.47 by $0.05. The company had revenue of $280.60 million for the quarter, compared to the consensus estimate of $250.17 million. During the same quarter last year, the company posted $1.34 earnings per share. United Therapeutics Corp.’s revenue was up 24.4% compared to the same quarter last year. Analysts expect that United Therapeutics Corp. will post $6.00 EPS for the current fiscal year.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.